EN DE
Watch Tanvex BioPharma Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Tanvex BioPharma Inc (6541) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Tanvex BioPharma Inc stock TWD 5.81, price TWD 29.10, that is 80.0% below the price, quality 23 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN KYG8676P1037

TB Tanvex BioPharma Inc logo Thin data Nov 6, 2026

Tanvex BioPharma Inc

6541 · TW
Very expensive, weak quality

Our calculation puts a fair price 80% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +321.9 %/yr in TWD)
Fair value 5.81 TWD · Strongly overvalued
Quality 23/100
Negative free cash flow
Trails peers (3/9)
Narrow moat 9/100
Thin data
Watch Tanvex BioPharma Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

228.00 TWD 26.90 TWD Fair Value 5.81 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range 26.90 TWD – 228.00 TWD · fair‑value band 4.34 TWD – 8.67 TWD · the 29.10 TWD price screens above the 5.81 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Tanvex BioPharma in your weekly email

Every Wednesday you see whether Tanvex BioPharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States.

Show moreShow less

The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines.

The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.

Stock analysis

Tanvex BioPharma Inc (6541) currently trades at 29.10 TWD, while our model-based Fair Value estimate is 5.81 TWD, 80% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: 4.34 TWD (bear) to 8.67 TWD (bull), the price of 29.10 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Tanvex BioPharma Inc reported revenue of 401M TWD in FY2025 versus 5.4M TWD in FY2021, a compound +193.5%/yr. Reported net income was −1.5B TWD in FY2025.

Key figures

Market cap 7.7B TWD (≈ $235M) Micro · P/S ratio 12.1 · EPS (TTM) −5.59 TWD · Return on equity −29.8% · Return on assets (EBIT) −44.2% (5-year average) · Operating margin −167% · Revenue (TTM) 658M TWD · Revenue growth (YoY) +371%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 54% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −80%, 6541 screens richer than that median.

Fair Value models

Bear 4.34 TWD Fair Value 5.81 TWD Bull 8.67 TWD
Price 29.10 TWD · Downside -80.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 4.34 TWD 5.81 TWD 8.67 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 4.34 TWD 5.81 TWD 8.67 TWD 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 23/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 71
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 25/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,056.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+161.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+321.9%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−695,214.0% (2020) → −346.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6541 screens overvalued: fair value 80% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Tanvex BioPharma Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 23 · Bottom 25%
Fair Value upside −80.0% · Bottom 25%
Profitability
Return on assets −18.8% · Below median
Operating margin (12 months) −166.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 370.8% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.35× · Cheaper than median
P/S (12 months) 11.73× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6541
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6541
Samsung Biologics Co 207940 1,510,000 KRW 1,667,600 KRW +10% vs 6541
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6541
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6541
WuXi Biologics (Cayman) Inc 2269 HK$48.92 HK$52.38 +7% vs 6541
argenx SE ARGX $927.21 $908.40 −2% vs 6541
CSL Limited CSL A$200.77 A$183.04 −9% vs 6541
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs 6541
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6541

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tanvex BioPharma Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Tanvex BioPharma Inc Fair Value". https://www.fairvalue-calculator.com/stock/6541

Frequently asked questions

Is Tanvex BioPharma Inc (6541) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 5.81 TWD versus a price of 29.10 TWD, about 80% lower (overvalued).
What is the fair value of 6541?
Our model-based fair value for Tanvex BioPharma Inc is 5.81 TWD (as of Nov 6, 2026), built from audited fundamentals. The current price: 29.10 TWD.
What is the quality score of 6541?
Tanvex BioPharma Inc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tanvex BioPharma Inc (6541)?
Our model-based price target is the fair value of 5.81 TWD (as of Nov 6, 2026) from 1 valuation models. Cautious scenario 4.34 TWD, optimistic scenario 8.67 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Tanvex BioPharma Inc stock forecast for 2026?
Our models put fair value at 5.81 TWD, about 80% lower versus a price of 29.10 TWD (overvalued). Cautious scenario 4.34 TWD, optimistic scenario 8.67 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Tanvex BioPharma Inc (6541)?
Tanvex BioPharma Inc reported trailing-twelve-month revenue of about 658M TWD (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Tanvex BioPharma Inc (6541)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tanvex BioPharma Inc it is 5.81 TWD per share (as of Nov 6, 2026), against a price of 29.10 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Tanvex BioPharma Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 6541 trades above its calculated fair value: price 29.10 TWD, fair value 5.81 TWD, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6541?
No. The price is what the market pays today (29.10 TWD); the fair value is what the company's own numbers justify (5.81 TWD). For Tanvex BioPharma Inc the two are 23.29 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Tanvex BioPharma Inc worth?
The market values Tanvex BioPharma Inc at about 7.7B TWD (market capitalisation, as of Nov 6, 2026). Per share that is 29.10 TWD; our models calculate a fair value of 5.81 TWD per share.
What do the bullish and bearish scenarios say about 6541?
Our models span a range for Tanvex BioPharma Inc: cautious scenario 4.34 TWD, base 5.81 TWD, optimistic 8.67 TWD per share (as of Nov 6, 2026, price 29.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Tanvex BioPharma Inc (6541)?
Balance-sheet figures for Tanvex BioPharma Inc (as of Nov 6, 2026): return on equity −29.8%. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is 6541 from its 52-week high?
Tanvex BioPharma Inc trades at 29.10 TWD, about 54% below its 52-week high of 63.30 TWD and 8% above the low of 26.90 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 5.81 TWD is for.
Which stocks are comparable to Tanvex BioPharma Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tanvex BioPharma Inc stock attractive at the current price?
The data as of Nov 6, 2026: price 29.10 TWD, calculated fair value 5.81 TWD (−80%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6541 calculated?
We run Tanvex BioPharma Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 5.81 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Tanvex BioPharma Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tanvex BioPharma Inc (6541)?
The closing price on Nov 9, 2026 was 29.10 TWD. Our model-based fair value is 5.81 TWD, about 80% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tanvex BioPharma Inc right now?
The price sits above even our optimistic bull case (8.67 TWD). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (4.34 TWD to 8.67 TWD) leaves room in how you read the outcome.

Key figures of Tanvex BioPharma Inc

How large is the market capitalisation of Tanvex BioPharma Inc (6541)?
The market capitalisation of Tanvex BioPharma Inc is 7.7B TWD (≈ $235M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tanvex BioPharma Inc (6541)?
The price-to-sales ratio of Tanvex BioPharma Inc is 12.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tanvex BioPharma Inc (6541)?
Earnings per share at Tanvex BioPharma Inc are −5.59 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Tanvex BioPharma Inc (6541)?
The return on equity (ROE) of Tanvex BioPharma Inc is −29.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tanvex BioPharma Inc (6541)?
On an EBIT basis the return on assets of Tanvex BioPharma Inc is −44.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tanvex BioPharma Inc (6541)?
The operating margin of Tanvex BioPharma Inc is −167% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tanvex BioPharma Inc (6541)?
Revenue at Tanvex BioPharma Inc is growing +371% versus a year earlier (3y avg +162%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Tanvex BioPharma Inc (6541) generate?
The free cash flow of Tanvex BioPharma Inc is −1.7B TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tanvex BioPharma Inc (6541) carry?
The net debt of Tanvex BioPharma Inc is 700M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Tanvex BioPharma Inc in the live analysis

One click puts Tanvex BioPharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.